Prevention of Serious Adverse Events Following Angiography

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5177 participants.

Also called NCT01467466

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 5,177 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01467466
Other papers using this trial's data
  • Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine The New England journal of medicine, 2018-02-15 DOI, PubMed 29130810

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Malaysia, New Zealand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01467466. Randomized; double masking; primary purpose prevention. Start 2013-10-07 (actual); primary completion 2017-09-29 (actual). Results posted on 2018-11-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Prevention of Serious Adverse Events Following Angiography
Acronym
PRESERVE
Condition
Acute Renal Failure
Condition
Kidney Disease
Intervention (Drug)
IV isotonic saline
Intervention (Drug)
IV isotonic bicarbonate
Intervention (Drug)
N-acetylcysteine
Intervention (Drug)
Placebo
Lead sponsor
VA Office of Research and Development (class: US federal agency)
Collaborator
The George Institute (class: other)

Record details

Record id
cardio:ct-nct01467466
Content hash
e611b5e6e612ed54a5e4331131f8983dc5f3ff2d80e6efdce0070e5eaefb1e39